Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Harvard Catalyst system email notifications, as well as Search are currently experiencing problems. We are working to restore these as quickly as possible. If you have questions please email feedback@catalyst.harvard.edu.
Keywords
Last Name
Institution

profileMatthew Aaron Cavender, M.D.

TitleClinical Fellow in Medicine (EXT)
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Womens Hospital
Cardiology
75 Francis St
Boston MA 02115
vCardDownload vCard (login for email)

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cavender MA, Kaul P. Is It Time for Radial Access to Become a Quality Metric for Percutaneous Coronary Intervention? Circ Cardiovasc Interv. 2016 May; 9(5). PMID: 27162220.
    View in: PubMed
  2. O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1591-9. PMID: 27043082.
    View in: PubMed
  3. Cavender MA, Scirica BM, Raz I, Gabriel Steg P, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. Am J Med. 2016 Mar; 129(3):340.e1-8. PMID: 26524706.
    View in: PubMed
  4. Wang TY, McCoy LA, Bhatt DL, Rao SV, Roe MT, Resnic FS, Cavender MA, Messenger JC, Peterson ED. Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction. Am Heart J. 2016 Feb; 172:9-18. PMID: 26856210.
    View in: PubMed
  5. Boyden TF, Joynt KE, McCoy L, Neely ML, Cavender MA, Dixon S, Masoudi FA, Peterson E, Rao SV, Gurm HS. Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. Am Heart J. 2015 Dec; 170(6):1227-33. PMID: 26678645.
    View in: PubMed
  6. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg G, Bhatt DL. Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation. 2015 Aug 11; 132(6):e121-2. PMID: 26260506.
    View in: PubMed
  7. Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015 Sep 8; 132(10):923-31. PMID: 26152709.
    View in: PubMed
  8. Cavender MA, Faxon DP. Can BRIGHT restore the glow of bivalirudin? JAMA. 2015 Apr 7; 313(13):1323-4. PMID: 25774963.
    View in: PubMed
  9. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015 May; 3(5):356-66. PMID: 25791290.
    View in: PubMed
  10. Cavender MA, Joynt KE, Parzynski CS, Resnic FS, Rumsfeld JS, Moscucci M, Masoudi FA, Curtis JP, Peterson ED, Gurm HS. State mandated public reporting and outcomes of percutaneous coronary intervention in the United States. Am J Cardiol. 2015 Jun 1; 115(11):1494-501. PMID: 25891991.
    View in: PubMed
  11. O'Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DA. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J. 2015 May; 169(5):622-630.e6. PMID: 25965709.
    View in: PubMed
  12. Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24; 131(12):1047-53. PMID: 25681464; PMCID: PMC4365950.
  13. Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015 Apr; 38(4):696-705. PMID: 25552421.
    View in: PubMed
  14. Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchástegui M, Oude Ophuis T, van Hessen M, Mega JL. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2015 Oct; 4(5):468-74. PMID: 25318481.
    View in: PubMed
  15. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130(18):1579-88. PMID: 25189213.
    View in: PubMed
  16. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014 Aug 16; 384(9943):599-606. PMID: 25131979.
    View in: PubMed
  17. Bhatt DL, Cavender MA. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? JACC Heart Fail. 2014 Dec; 2(6):583-5. PMID: 24998081.
    View in: PubMed
  18. Cavender MA, Rassi AN, Schwamm LH, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Bhatt DL. Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. Clin Cardiol. 2014 May; 37(5):323. PMID: 24596074.
    View in: PubMed
  19. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15; 311(3):252-62. PMID: 24247616.
    View in: PubMed
  20. Cavender MA, Rassi AN, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Schwamm LH, Bhatt DL. Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Clin Cardiol. 2013 Dec; 36(12):749-56. PMID: 24085713.
    View in: PubMed
  21. Chan PS, Rao SV, Bhatt DL, Rumsfeld JS, Gurm HS, Nallamothu BK, Cavender MA, Kennedy KF, Spertus JA. Patient and hospital characteristics associated with inappropriate percutaneous coronary interventions. J Am Coll Cardiol. 2013 Dec 17; 62(24):2274-81. PMID: 24055743; PMCID: PMC3864986.
  22. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3; 369(14):1317-26. PMID: 23992601.
    View in: PubMed
  23. Cavender MA, Rajeswaran J, DiPaola L, Houghtaling P, Kiernan MS, Rassi AN, Menon V, Whitlow PW, Ellis SG, Shishehbor MH. Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shock. J Invasive Cardiol. 2013 May; 25(5):218-24. PMID: 23645045.
    View in: PubMed
  24. Bhatt DL, Cavender MA. Are all clinical trial sites created equal? J Am Coll Cardiol. 2013 Feb 5; 61(5):580-1. PMID: 23246386.
    View in: PubMed
  25. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 8; 61(1):35-40. PMID: 23137936.
    View in: PubMed
  26. Cavender MA, Ellis SG. Stent choice and the hidden consequences of cost savings. Nat Rev Cardiol. 2012 Oct; 9(10):559-60. PMID: 22922596.
    View in: PubMed
  27. Rassi AN, Blackstone E, Militello MA, Theodos G, Cavender MA, Sun Z, Ellis SG, Cho L. Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Am J Cardiol. 2012 Aug 15; 110(4):485-90. PMID: 22591672.
    View in: PubMed
  28. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012 Feb; 26(1):71-5. PMID: 22109255.
    View in: PubMed
  29. Cavender MA, Rao SV. Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms? J Thromb Thrombolysis. 2010 Oct; 30(3):332-9. PMID: 20464453.
    View in: PubMed
  30. Cavender MA, Nicholls SJ, Lincoff AM. Strategies for the development of new PPAR agonists in diabetes. Eur J Cardiovasc Prev Rehabil. 2010 May; 17 Suppl 1:S32-7. PMID: 20489419.
    View in: PubMed
  31. Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-a/? agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010; 10(4):209-16. PMID: 20653327.
    View in: PubMed
  32. Cavender MA, Alexander KP, Broderick S, Shaw LK, McCants CB, Kempf J, Ohman EM. Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease. Am Heart J. 2009 Dec; 158(6):933-40. PMID: 19958859.
    View in: PubMed
  33. Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2009 Aug 15; 104(4):507-13. PMID: 19660603.
    View in: PubMed
  34. Cavender MA, Ohman EM. What do you need to know before performing a percutaneous coronary intervention? Circulation. 2008 Aug 5; 118(6):609-11. PMID: 18678781.
    View in: PubMed
  35. Cavender MA, Rao SV, Ohman EM. Major bleeding: management and risk reduction in acute coronary syndromes. Expert Opin Pharmacother. 2008 Aug; 9(11):1869-83. PMID: 18627326.
    View in: PubMed
  36. Benza RL, Cavender MA, Barchue J, Tallaj JA, Bourge RC, Kirklin JK, Coffey CS. Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern. J Heart Lung Transplant. 2007 May; 26(5):494-7. PMID: 17449419; PMCID: PMC1950728.
  37. Benza RL, Anderson PG, Lyle K, Barchue J, de Oliveira AL, Cavender MA, Pinderski LJ, George JF. Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. J Heart Lung Transplant. 2003 May; 22(5):515-8. PMID: 12742412.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For demographic and contact information changes only, HMS/HSDM faculty should contact Human Resources at human_resourceshms.harvard.edu.
Cavender's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description